12:37 PM EDT, 07/29/2024 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) said Monday that a committee of the European Medicines Agency recommended the approval of its proposed Rituximab biosimilar in European markets.

EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending the launch of Dr. Reddy's DRL_RI in Europe.

The approval is subject to final sign off from the European Commission.

Price: 82.48, Change: +1.26, Percent Change: +1.55